The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Tumor-Informed Minimal Residual Disease (MRD) Tests Market Over The 2026–2030 Period?
The market size for tumor-informed minimal residual disease (MRD) tests has expanded rapidly in recent years. This market is projected to grow from $1.14 billion in 2025 to $1.32 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 15.6%. Historically, this expansion has been driven by factors such as an increase in cancer prevalence, advancements in genetic sequencing, the demand for post-treatment monitoring, regulatory approvals for molecular diagnostics, and the adoption of PCR and NGS technologies.
The tumor-informed minimal residual disease (MRD) tests market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $2.37 billion by 2030, exhibiting a robust compound annual growth rate (CAGR) of 15.8%. This projected growth is driven by factors such as the rise of personalized medicine, the application of AI-driven data analytics for MRD, increased oncology research, the creation of non-invasive diagnostic assays, and seamless integration with hospital IT systems. Key developments expected during this period involve personalized MRD monitoring, incorporating these tests into clinical decision support systems, the adoption of non-invasive sample analysis, enhanced high-sensitivity ctDNA detection, and advanced predictive disease recurrence modeling.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Primary Drivers Are Impacting The Tumor-Informed Minimal Residual Disease (MRD) Tests Market Growth?
The increasing incidence of cancer is projected to drive the expansion of the tumor-informed minimal residual disease (MRD) tests market in the coming years. Cancer encompasses various conditions marked by the unrestrained proliferation and division of irregular cells, capable of infiltrating adjacent tissues and disseminating throughout the body. This rising occurrence of cancer stems from unhealthy lifestyle choices, such as inadequate nutrition, insufficient physical exercise, tobacco use, and excessive alcohol intake, all of which elevate the likelihood of developing diverse cancer types. Tumor-informed minimal residual disease (MRD) tests assist in managing cancer by identifying minute quantities of genetic material specific to cancer following treatment, thereby facilitating early detection of recurrence and informing tailored therapeutic strategies. For example, the World Health Organization, an international entity based in Switzerland focused on global health policy and public health endeavors, projected in February 2024 that more than 35 million new cancer cases will arise by 2050, representing a 77% surge from the approximately 20 million cases observed in 2022. Consequently, the escalating incidence of cancer is accelerating the expansion of the tumor-informed minimal residual disease (MRD) tests market.
What Segment Categories Shape The Tumor-Informed Minimal Residual Disease (MRD) Tests Market Segment Landscape?
The tumor-informed minimal residual disease (MRD) tests market covered in this report is segmented –
1) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction (PCR)-based, Other Technologies
2) By Product Type: Assay Kits, Instruments, Software, Services
3) By Sample Type: Peripheral Blood (Ctdna), Bone Marrow, Tissue Biopsy, Other Body Fluids
4) By Application: Colorectal Cancer, Lung Cancer, Breast Cancer, Hematological Malignancies, Other Applications
5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutes, Other End-Users
Subsegments:
1) By Next-Generation Sequencing: Targeted Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Single Cell Sequencing, Other Sequencing Approaches
2) By Polymerase Chain Reaction (PCR)-Based: Digital Polymerase Chain Reaction, Real Time Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Other Polymerase Chain Reaction Methods
3) By Other Technologies: Hybrid Capture Based, Bead Based Assays, Electrochemical Detection, Other Emerging Technologies
What Market Trends Are Affecting The Tumor-Informed Minimal Residual Disease (MRD) Tests Market?
Companies prominent in the tumor informed minimal residual disease (MRD) tests market are concentrating on creating advanced solutions, such as tissue informed whole genome sequencing (WGS) MRD assays. These are designed to identify extremely low concentrations of circulating tumor DNA, facilitating the early identification of cancer recurrence and effectiveness of treatment. A tissue-informed whole genome sequencing (WGS) MRD assay operates by using a patient’s tumor sample to pinpoint specific genetic alterations, subsequently monitoring the blood for these same mutations to identify minimal residual disease at minute levels. As an illustration, Foundation Medicine, Inc., a precision medicine firm based in the US, introduced its Tissue-informed WGS MRD test through the FlexOMx Lab in September 2025. This novel, tumor-informed whole-genome sequencing test for molecular residual disease is intended for research applications spanning early to late-stage cancers. It meticulously monitors hundreds to thousands of tumor-specific variants in circulating tumor DNA with significant accuracy, thereby enabling the precise detection of minimal residual disease even when tumor levels are very low, while simultaneously offering extensive genomic profiling to deepen comprehension of recurrence and resistance to treatment in clinical investigations.
Who Are The Companies Operating Across The Tumor-Informed Minimal Residual Disease (MRD) Tests Market Value Chain?
Major companies operating in the tumor-informed minimal residual disease (MRD) tests market are Roche Diagnostics International Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, Illumina Inc., Bio-Rad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Integrated DNA Technologies Inc., Natera Inc., NeoGenomics Laboratories Inc., Veracyte Inc., Foundation Medicine Inc., Adaptive Biotechnologies Corporation, Genetron Holdings Limited, Burning Rock Biotech Co Ltd., Personalis Inc., Foresight Diagnostics Inc., Predicine Inc., Guardant Health Inc.
Get The Full Tumor-Informed Minimal Residual Disease (MRD) Tests Market Report:
Which Region Leads The Tumor-Informed Minimal Residual Disease (MRD) Tests Market In Terms Of Market Share?
North America was the largest region in the tumor-informed minimal residual disease (MRD) tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor-informed minimal residual disease (MRD) tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Tumor-Informed Minimal Residual Disease (MRD) Tests Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Tumor-Informed Minimal Residual Disease (MRD) Tests Market 2026, By The Business Research Company
pruritus therapeutic market report 2026
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
genomic urine testing market report 2026
https://www.thebusinessresearchcompany.com/report/genomic-urine-testing-global-market-report
ocular genetic diagnostic market report 2026
https://www.thebusinessresearchcompany.com/report/ocular-genetic-diagnostic-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model